PFE - Vaccine Player Vaxcyte Can Potentially Disrupt Pfizer's 20-Plus-Year Near Monopoly Says Analyst | Benzinga
Mizuho Securities initiated coverage on Vaxcyte Inc (NASDAQ: PCVX), a vaccine company targeting bacterial infectious diseases (primarily for disease prevention).
Lead asset VAX-24 is set to enter the Phase 3 stage of development in 2024 for pneumococcal disease.
Topline data from the Phase 3 study is expected in 2025, and Phase 2 infants in late 2024/early 2025.
The Mizuho analyst writes that Pfizer Inc (NYSE: PFE) has maintained a 20-plus-year near monopoly with its Prevnar family of pneumococcal vaccines. However, the same PCV technology has hit its limit at ~20 serotypes.
Vaxcyte ...